{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=81",
    "query": {
      "condition": "Relapsed/Refractory",
      "page": 81
    },
    "page_size": 10
  },
  "pagination": {
    "page": 81,
    "page_size": 10,
    "total_count": 3666,
    "total_pages": 367,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=82&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=80&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T23:53:21.846Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01236586",
      "title": "RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Brain Neoplasms",
        "Sarcoma",
        "Osteosarcoma",
        "Wilm's Tumor"
      ],
      "interventions": [
        {
          "name": "RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-10-08",
      "completion_date": "2011-04-13",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Memphis, Tennessee",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01236586"
    },
    {
      "nct_id": "NCT00588094",
      "title": "Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "B-cell Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 20,
      "start_date": "2003-10",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2015-12-04",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588094"
    },
    {
      "nct_id": "NCT00364923",
      "title": "Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pralatrexate Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acrotech Biopharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2006-08",
      "completion_date": "2009-02-24",
      "has_results": true,
      "last_update_posted_date": "2019-12-19",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 18,
      "location_summary": "Duarte, California • Los Angeles, California • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00364923"
    },
    {
      "nct_id": "NCT01134341",
      "title": "Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous T-cell Lymphoma",
        "Mycosis Fungoides",
        "Sezary Syndrome",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pralatrexate Injection",
          "type": "DRUG"
        },
        {
          "name": "Bexarotene Capsules",
          "type": "DRUG"
        },
        {
          "name": "Vitamin B12",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Folic Acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Acrotech Biopharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2010-03",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2019-12-18",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 4,
      "location_summary": "Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01134341"
    },
    {
      "nct_id": "NCT06563596",
      "title": "Epco, Zanu, Ritux for R/R FL or MZL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Relapsed Lymphoma",
        "Refractory Lymphoma",
        "Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Epcoritamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reid Merryman, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2025-01-21",
      "completion_date": "2032-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06563596"
    },
    {
      "nct_id": "NCT02624986",
      "title": "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Idasanutlin",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-12-23",
      "completion_date": "2019-05-20",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Louisville, Kentucky + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Cary",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02624986"
    },
    {
      "nct_id": "NCT02049541",
      "title": "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "PI3K inhibitor BKM120",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacodynamics",
          "type": "OTHER"
        },
        {
          "name": "Correlative studies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Kami Maddocks, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2014-07-21",
      "completion_date": "2019-04-09",
      "has_results": false,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Columbus, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02049541"
    },
    {
      "nct_id": "NCT00042341",
      "title": "Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Lymphoblastic, Acute, Pediatric"
      ],
      "interventions": [
        {
          "name": "clofarabine (IV formulation)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 60,
      "start_date": "2002-05",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2022-05-27",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Orange County, California • San Diego, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange County",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042341"
    },
    {
      "nct_id": "NCT00949988",
      "title": "A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib and Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2009-05",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2019-08-14",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949988"
    },
    {
      "nct_id": "NCT01596127",
      "title": "Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoid Malignancies",
        "Metastatic Malignant Neoplasm to the Leptomeninges"
      ],
      "interventions": [
        {
          "name": "Intrathecal Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2013-01-24",
      "completion_date": "2017-03-23",
      "has_results": true,
      "last_update_posted_date": "2018-05-24",
      "last_synced_at": "2026-11-14T23:53:21.846Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01596127"
    }
  ]
}